You Can Outsource the Work, Not the Risk

Outsourcing has become the backbone of modern pharmaceutical and medical device operations. Sponsors increasingly rely on Contract Development and Manufacturing Organizations (CDMOs) for speed, expertise, and scalability. But as outsourcing continues to expand, so does regulatory oversight. The FDA and EMA have made it clear: while CDMOs perform the work, sponsors remain ultimately responsible for the quality and compliance of their products.

Outsourced does not mean out of scope.

It’s an important distinction, and one that many companies underestimate. The efficiency gained through outsourcing can quickly erode if oversight isn’t clearly defined. I’ve seen situations where well-intentioned sponsors placed full trust in their CDMOs, only to discover too late that what they assumed was being managed wasn’t being managed at all.

Where the Risks Hide

Most compliance issues in outsourced manufacturing can be traced back to a single, deceptively simple problem: unclear expectations. Weak or overly generic quality agreements often leave critical details open to interpretation. When those expectations are not clearly documented, each side operates under its own assumptions.

Consider a common scenario. A sponsor believes the CDMO is conducting full stability testing, but the CDMO interprets “testing” differently, focusing only on specific attributes. The gap isn’t discovered until a product release is delayed and an FDA 483 follows. It’s not a failure of competence but a failure of clarity.

Limited visibility into CDMO operations, inconsistent change control, and an overreliance on trust instead of data compound the issue. The sponsor may feel comfortable because the relationship is strong, but regulators don’t evaluate trust. They evaluate evidence.

When Drugs Meet Devices

The risks become even more complex when combination products enter the mix. These products blur the regulatory lines between pharmaceuticals and medical devices, bringing both 21 CFR 210/211 and 820 into play. Suddenly, oversight is split, and questions arise about who owns which part of the process. Who is responsible for design controls? Who maintains complaint records? Whose documentation takes precedence when issues arise?

Without a unified quality system and cross-functional communication, these projects can quickly become tangled. A lack of integration between teams often leads to missed documentation, inconsistent traceability, or delayed investigations. The more hybrid the product, the greater the need for alignment and that alignment must begin with structure, not reaction.

Managing Risk with Intention

Strong risk management is what bridges the gap between assumption and assurance. Frameworks like ICH Q9 give sponsors a practical way to identify, assess, and prioritize risks associated with their CDMOs. By linking risk assessments directly to the quality agreement, sponsors can ensure that oversight activities are proportional to the level of risk and not just the size of the contract.

Tools such as FMEAs and risk registers are valuable, but they’re only effective when used consistently. Risk management isn’t a one-time exercise performed at project launch; it’s a living process that evolves as operations change. Periodic risk reviews within the quality management system keep oversight relevant and actionable, helping sponsors anticipate problems instead of reacting to them.

When applied correctly, risk management transforms oversight from a checklist into a strategy. It creates transparency, accountability, and a stronger compliance posture for both the sponsor and the CDMO.

Safeguarding Accountability

In the end, sponsors cannot outsource accountability. They remain the ultimate risk owners, responsible for ensuring that products are safe, effective, and compliant. Strong quality agreements, open communication, and structured risk management are not just regulatory expectations. They are the foundation of successful partnerships.

Effective oversight isn’t about micromanaging your CDMO; it’s about creating a system where expectations are shared, performance is visible, and quality is mutual. That’s how sponsors safeguard not just compliance, but also trust, reputation, and ultimately, patient safety.

Because you can outsource operations, but not accountability.

At Quality Systems Services LLC, we help sponsors and CDMOs build stronger, clearer partnerships rooted in transparency and compliance.

If you’re preparing to outsource manufacturing or want to strengthen your current oversight practices, let’s talk about how to design risk-based systems that protect both your products and your reputation.

Contact Us